INTRODUCTION {#s1}
============

Breast cancer is the most common malignancy tumor among women, which accounts for 25% of all cancer cases in women all over the world, and it is the principal cause of female cancer-related death \[[@R1]\]. In the United States alone, a total of more than 2.8 million women suffered from breast cancer in 2015, and the morbidity of breast cancer is still increasing fast in recent years, so breast cancer has become a serious threat to the health and life of women worldwide \[[@R2]\]. The occurrence and development of breast cancer is a multistep, multistage complicated process involving multiple factors, among which genetic factors are considered to play a crucial role \[[@R3]\]. Consequently, identifying susceptible gene of breast cancer is of great importance, which can lead to better diagnosis, treatment and possible prevention of breast cancer.

MicroRNAs (miRNAs) are a class of non-coding single-stranded RNA molecules of about twenty-two nucleotides encoded by endogenous genes. By binding to the complementary sequence of the 3′ untranslated region of the specific target gene mRNA, microRNAs can degrade mRNA or inhibit its translation, and thus regulate the expression of target gene \[[@R4]\]. MiRNAs are highly conserved, tissue-specific and taking part in the regulation of many physiological and pathological process, such as cell differentiation, cell proliferation, cell apoptosis, fat metabolism, etc \[[@R5], [@R6]\]. MiRNAs have many important functions: among them, the function of microRNAs in cancer occurrence and progression attracts the most attention \[[@R7]\].

Studies have reported that single nucleotide polymorphisms (SNPs) or genetic mutations occurring in miRNAs could affect the efficiency of miRNA binding to the target sites of mRNA and alter the expression of related gene, which may involve acquisition of cancer susceptibility, so miRNAs play an important role in initiation and development of malignancies \[[@R8]\]. So far there are many studies about microRNA polymorphisms (miR-499 rs3746444, miR-196a rs11614913 and miR-146a rs2910164) and breast cancer susceptibility, but the results are controversial \[[@R9]--[@R26]\]. In addition, two meta-analyses on this issue published in 2013 and 2015 yielded inconsistent results: one reported that rs3746444 and rs2910164 were not associated with breast cancer risk \[[@R27]\], while another showed that these two microRNA polymorphisms could increase breast cancer susceptibility \[[@R28]\]. Therefore, we conducted this meta-analysis including some latest studies to make a more accurate and comprehensive assessment of these three polymorphisms and breast cancer risk.

RESULTS {#s2}
=======

Characteristics of included studies {#s2_1}
-----------------------------------

The complete search process is presented in Figure [1](#F1){ref-type="fig"}. A total of 242 publications were preliminarily identified according to the search strategy described in the methods and materials section. After removing duplicate articles, 168 records remained. Then we read titles and abstracts of all the studies and excluded 145 articles that were obviously unrelated. After carefully reviewing the full texts of the remaining articles, an additional five articles were excluded, including two articles that had no sufficient data and three articles that contained re-reported data. Ultimately, thirty-eight eligible studies from eighteen remaining articles \[[@R9]--[@R26]\], including 17,417 cases and 18,988 cancer-free controls, were eventually included in our meta-analysis. The characteristics of the thirty-eight eligible studies are presented in Table [1](#T1){ref-type="table"}. Among these included studies, twenty-five were performed in Asians \[[@R9], [@R11]--[@R16], [@R20]--[@R22]\], twelve in Caucasians \[[@R10], [@R17]--[@R18], [@R23]--[@R26]\], and one in mixed ethnicity \[[@R19]\]. All the cases in the included studies were in accordance with the pathological diagnostic criteria of breast cancer and all the papers were published between 2009 and 2016.

![Flow diagram of the selection of the studies in this meta-analysis](oncotarget-08-393-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  First author          Year   Country     Ethnicity   Genotyping method   Number (case/control)   HWE (*P* value)
  --------------------- ------ ----------- ----------- ------------------- ----------------------- -----------------
  rs3746444                                                                                        
  Hu\[[@R9]\]           2009   China       Asian       PCR-RFLP            1009/1093               0.057
  Catucci\[[@R10]\]     2010   Italy       Caucasian   Taqman              756/1242                0.250
  Catucci\[[@R10]\]     2010   Germany     Caucasian   Taqman              823/925                 0.893
  Alshatwi\[[@R11]\]    2012   Saudi       Asian       Taqman              100/100                 0.227
  Bansal\[[@R12]\]      2014   India       Asian       PCR-RFLP            121/164                 0.261
  Omrani\[[@R13]\]      2014   Iran        Asian       TARMS-PCR           236/203                 0.241
  Qi\[[@R14]\]          2015   China       Asian       Taqman              321/290                 0.053
  He\[[@R15]\]          2015   China       Asian       MassARRAY           450/450                 0.143
  Dai\[[@R16]\]         2016   China       Asian       MassARRAY           560/583                 0.131
  rs11614913                                                                                       
  Hu\[[@R9]\]           2009   China       Asian       PCR-RFLP            1009/1093               0.210
  Hoffman\[[@R17]\]     2009   USA         Caucasian   MassARRAY           426/466                 0.583
  Catucci\[[@R10]\]     2010   Italy       Caucasian   Taqman              751/1243                0.315
  Catucci\[[@R10]\]     2010   Germany     Caucasian   Taqman              1101/1496               0.711
  Jedlinski\[[@R18]\]   2011   Australia   Caucasian   PCR-RFLP            187/171                 0.830
  Alshatwi\[[@R11]\]    2012   Saudi       Asian       Taqman              100/100                 0.032
  Linhares\[[@R19]\]    2012   Brazil      Mixed       Taqman              388/388                 0.005
  Zhang\[[@R20]\]       2012   China       Asian       PCR-RFLP            248/243                 0.893
  Ma\[[@R21]\]          2013   China       Asian       MassARRAY           190/187                 0.037
  Bansal\[[@R12]\]      2014   India       Asian       PCR-RFLP            121/165                 0.042
  Omrani\[[@R13]\]      2014   Iran        Asian       TARMS-PCR           236/203                 0.000
  Qi\[[@R14]\]          2015   China       Asian       Taqman              321/290                 0.141
  He\[[@R15]\]          2015   China       Asian       MassARRAY           450/450                 0.990
  Zhang\[[@R22]\]       2015   China       Asian       MassARRAY           379/187                 0.037
  Dai\[[@R16]\]         2016   China       Asian       MassARRAY           560/583                 0.540
  Morales\[[@R23]\]     2016   Chile       Caucasian   Taqman              440/807                 0.121
  rs2910164                                                                                        
  Hu\[[@R13]\]          2009   China       Asian       PCR-RFLP            1009/1093               0.221
  Catucci\[[@R10]\]     2010   Germany     Caucasian   Taqman              805/904                 0.753
  Catucci\[[@R10]\]     2010   Italy       Caucasian   Taqman              754/1243                0.019
  Pastrello\[[@R24]\]   2010   Italy       Caucasian   Sequencing          88/155                  0.332
  Garcia\[[@R25]\]      2011   France      Caucasian   Taqman              1130/596                0.150
  Alshatwi\[[@R11]\]    2012   Saudi       Asian       Taqman              100/100                 0.051
  Ma\[[@R21]\]          2013   China       Asian       MassARRAY           192/191                 0.983
  Bansal\[[@R12]\]      2014   India       Asian       PCR-RFLP            121/164                 0.130
  Omrani\[[@R13]\]      2014   Iran        Asian       TARMS-PCR           236/203                 0.000
  Qi\[[@R14]\]          2015   China       Asian       Taqman              321/290                 0.013
  He\[[@R15]\]          2015   China       Asian       MassARRAY           450/490                 0.478
  Zhang\[[@R22]\]       2015   China       Asian       MassARRAY           382/191                 0.983
  Upadhyaya\[[@R26]\]   2015   Australia   Caucasian   HRM                 546/246                 0.091

Abbreviations: HWE: Hardy-Weinberg equilibrium for controls. PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism. TARMS-PCR: tetra-primer amplification refractory mutation system-polymerase chain reaction. HRM: High ResolutionMelting.

Meta-analysis results {#s2_2}
---------------------

Distribution and allele frequency of these three microRNA polymorphisms in cases and controls are shown in Table [2](#T2){ref-type="table"}, and the main results of this meta-analysis are presented in Table [3](#T3){ref-type="table"}. For rs3746444, the nine eligible studies with 4,376 breast cancer patients and 5,050 cancer-free controls were finally included. As shown in Table [3](#T3){ref-type="table"}, we observed an increased breast cancer risk associated with rs3746444 polymorphism in the four genetic models: allele contrast genetic model (OR = 1.17, 95% CI = 1.04--1.31, *P* = 0.008), homozygote genetic model (OR = 1.41, 95% CI = 1.19--1.67, *P* \< 0.001), heterozygote genetic model (OR = 1.10, 95% CI = 1.01--1.21, *P* = 0.036), and dominant genetic model (OR = 1.16, 95% CI = 1.06--1.26, *P* = 0.001). The stratified analysis by ethnicity showed an increased BC risk in Asians (allele contrast genetic model: OR = 1.08, 95% CI = 1.03--1.14, *P* = 0.001; homozygote genetic model: OR = 1.11, 95% CI = 1.03--1.21, *P* = 0.009; heterozygote genetic model: OR = 1.11, 95% CI = 1.03--1.20, *P* = 0.008; dominant genetic model: OR = 1.17, 95% CI = 1.07--1.29, *P* = 0.001). However, no meaningful correlation was observed in Caucasians (Table [3](#T3){ref-type="table"}) (Figure [2](#F2){ref-type="fig"}).

###### Genotype distribution and allele frequency of these three microRNA polymorphisms (miR-499 rs3746444, miR-196a rs11614913 and miR-146a rs2910164) in cases and controls

  First author                                                                                
  --------------------- ------ ----- ----- ----- ------ ----- ----- ----- ------ ----- ------ ------
  miR-499 rs3746444                                                                           
  Hu                    1009   707   258   44    1093   816   248   29    1672   346   1880   306
  Catucci               756    414   295   47    1242   704   452   86    1123   389   1860   624
  Catucci               823    536   250   37    925    601   290   34    1322   324   1492   358
  Alshatwi              100    30    62    8     100    45    40    15    78     122   70     130
  Bansal                121    80    30    11    164    106   43    15    190    52    255    73
  Omrani                236    131   44    61    203    130   48    25    306    166   308    98
  Qi                    321    152   117   52    290    141   112   37    421    221   394    186
  He                    450    184   177   89    450    203   188   59    545    355   594    306
  Dai                   560    407   135   18    583    463   109   11    949    171   1035   131
  miR-196a rs11614913                                                                         
  Hu                    1009   287   483   239   1093   358   517   218   1057   961   1233   953
  Hoffman               426    181   209   36    466    166   229   71    571    281   561    371
  Catucci               751    334   330   87    1243   532   550   161   998    504   1614   872
  Catucci               1101   432   512   157   1496   584   696   216   1376   826   1864   1128
  Jedlinski             187    68    86    33    171    58    82    31    222    152   198    144
  Alshatwi              100    35    63    2     100    46    50    4     133    67    142    58
  Linhares              388    94    177   117   388    127   165   96    365    411   419    357
  Zhang                 248    148   89    11    243    133   93    17    385    111   359    127
  Ma                    190    54    92    44    187    59    79    49    200    180   197    177
  Bansal                121    68    41    12    165    85    59    21    177    65    229    101
  Omrani                236    218   18    0     203    178   25    0     454    18    381    25
  Qi                    321    168   119   34    290    185   88    17    455    187   458    122
  He                    450    81    233   136   450    93    223   134   395    505   409    491
  Zhang                 379    108   181   90    187    59    79    49    397    361   197    177
  Dai                   560    197   265   98    583    155   284   144   659    461   594    572
  Morales               440    192   191   57    807    342   351   114   575    305   1035   579
  miR-146a rs2910164                                                                          
  Hu                    1009   329   515   165   1093   362   551   180   1173   845   1275   911
  Catucci               805    451   304   50    904    536   318   50    1206   404   1390   418
  Catucci               754    409   286   59    1243   650   520   73    1104   404   1820   666
  Pastrello             88     53    30    5     155    90    59    6     136    40    239    71
  Garcia                1130   676   388   66    596    352   220   24    1740   520   924    268
  Alshatwi              100    48    50    2     100    51    46    3     146    54    148    52
  Ma                    192    63    94    35    191    64    93    34    220    164   221    161
  Bansal                121    82    35    4     164    84    72    8     199    43    240    88
  Omrani                236    183   45    8     203    155   39    9     411    61    349    57
  Qi                    321    146   132   43    290    126   144   20    424    218   396    184
  He                    450    75    242   133   490    112   225   153   392    508   449    531
  Zhang                 382    126   181   75    191    64    93    34    433    331   221    161
  Upadhyaya             546    325   193   28    246    112   99    35    843    249   323    169

A: the major allele; B: the minor allele.

![Forest plots of associations between rs3746444 and breast cancer risk among different ethnic groups in heterozygote genetic model\
(**A**) the overall populations; (**B**) Asians; (**C**) Caucasians.](oncotarget-08-393-g002){#F2}

###### Meta-analysis results

  Comparisons                     OR     95%CI        P(OR) I^2^   Heterogeneity   Effects model   P(Begg)   P(Egger)   
  ------------------------------- ------ ------------ ------------ --------------- --------------- --------- ---------- -------
  Allele contrast genetic model                                                                                         
  rs3746444                       1.17   1.04--1.31   0.008        58%             0.014           R         0.602      0.796
  Asian                           1.24   1.08--1.42   0.002        48%             0.071           R         \-         \-
  Caucasian                       1.03   0.92--1.15   0.628        0%              0.924           F         \-         \-
  rs11614913                      0.98   0.89--1.09   0.748        73%             0.000           R         0.753      0.718
  Asian                           0.99   0.85--1.17   0.932        76%             0.000           R         \-         \-
  Caucasian                       0.93   0.87--1.00   0.044        37%             0.173           F         \-         \-
  rs2910164                       0.97   0.87--1.07   0.510        64%             0.001           R         0.161      0.292
  Asian                           1.02   0.94--1.10   0.702        16%             0.303           F         \-         \-
  Caucasian                       0.92   0.74--1.14   0.453        84%             0.000           R         \-         \-
  Homozygote genetic model                                                                                              
  rs3746444                       1.41   1.19--1.67   0.000        34%             0.147           F         1.000      0.768
  Asian                           1.64   1.34--2.02   0.000        0%              0.543           F         \-         \-
  Caucasian                       1.03   0.77--1.38   0.844        0%              0.381           F         \-         \-
  rs11614913                      0.95   0.77--1.16   0.600        71%             0.000           R         0.488      0.538
  Asian                           0.98   0.71--1.34   0.877        73%             0.000           R         \-         \-
  Caucasian                       0.85   0.73--0.99   0.037        52%             0.080           R         \-         \-
  rs2910164                       1.03   0.80--1.33   0.804        64%             0.001           R         0.246      0.554
  Asian                           1.11   0.94--1.32   0.221        0%              0.474           F         \-         \-
  Caucasian                       0.95   0.52--1.72   0.862        85%             0.000           R         \-         \-
  Heterozygote genetic model                                                                                            
  rs3746444                       1.10   1.01--1.21   0.036        26%             0.209           F         1.000      0.610
  Asian                           1.15   1.02--1.30   0.022        32%             0.186           F         \-         \-
  Caucasian                       1.04   0.91--1.20   0.572        0%              0.334           F         \-         \-
  rs11614913                      1.03   0.92--1.15   0.577        47%             0.019           R         0.964      0.671
  Asian                           1.07   0.89--1.28   0.481        57%             0.014           R         \-         \-
  Caucasian                       0.95   0.86--1.06   0.348        0%              0.887           F         \-         \-
  rs2910164                       0.95   0.83--1.08   0.403        54%             0.011           R         0.951      0.598
  Asian                           0.98   0.80--1.20   0.866        58%             0.019           R         \-         \-
  Caucasian                       0.91   0.77--1.07   0.241        51%             0.085           R         \-         \-
  Dominant genetic model                                                                                                
  rs3746444                       1.16   1.06--1.26   0.001        19%             0.272           F         0.466      0.332
  Asian                           1.25   1.12--1.40   0.000        0%              0.509           F         \-         \-
  Caucasian                       1.04   0.91--1.89   0.569        0%              0.536           F         \-         \-
  rs11614913                      1.01   0.89--1.15   0.837        66%             0.000           R         0.893      0.885
  Asian                           1.08   0.89--1.32   0.442        72%             0.000           R         \-         \-
  Caucasian                       0.93   0.84--1.02   0.136        0%              0.533           F         \-         \-
  rs2910164                       0.95   0.83--1.08   0.453        59%             0.003           R         0.855      0.478
  Asian                           1.00   0.83--1.19   0.960        50%             0.053           R         \-         \-
  Caucasian                       0.90   0.73--1.11   0.317        73%             0.005           R         \-         \-
  Recessive genetic model                                                                                               
  rs3746444                       1.29   0.97--1.71   0.083        66%             0.003           R         0.754      0.883
  Asian                           1.38   0.97--1.96   0.070        67%             0.006           R         \-         \-
  Caucasian                       1.01   0.75--1.34   0.971        11%             0.289           F         \-         \-
  rs11614913                      0.93   0.80--1.08   0.324        58%             0.002           R         0.138      0.286
  Asian                           0.98   0.79--1.21   0.843        62%             0.005           R         \-         \-
  Caucasian                       0.88   0.76--1.01   0.062        45%             0.120           F         \-         \-
  rs2910164                       1.03   0.82--1.29   0.784        62%             0.001           R         0.669      0.879
  Asian                           1.03   0.89--1.19   0.686        14%             0.319           F         \-         \-
  Caucasian                       1.00   0.57--1.73   0.986        83%             0.000           R         \-         \-

F: fixed effects model; R: random effects model.

For rs11614913, the association of this SNP with breast cancer risk was investigated in sixteen studies involving 6,907 cases and 8,072 control subjects. We failed to find a significant association between this polymorphism and BC risk in any of the five genetic models in the overall populations. However, in the subgroup analysis by ethnicity, we found rs11614913 was associated with a decreased risk of breast cancer among Caucasians in allele contrast genetic model (OR = 0.93, 95% CI = 0.87--1.00, *P* = 0.044) (Table [3](#T3){ref-type="table"}) (Figure [3](#F3){ref-type="fig"}).

![Forest plots of associations between rs11614913 and breast cancer risk among different ethnic groups in allele contrast genetic model\
(**A**) the overall populations; (**B**) Asians; (**C**) Caucasians.](oncotarget-08-393-g003){#F3}

For rs2910164, thirteen studies with 6,134 cases and 5,866 controls were used to assess the association between this genetic polymorphism and breast cancer susceptibility. No obvious association was found between the rs2910164 polymorphism and breast cancer risk in any of the five genetic models. Similarly, further stratified analysis by ethnicity showed no significant correlation between rs11614913 and breast cancer susceptibility in all the ethnic groups (Table [3](#T3){ref-type="table"}) (Figure [4](#F4){ref-type="fig"}).

![Forest plots of associations between rs2910164 and breast cancer risk among different ethnic groups in homozygote genetic model\
(**A**) the overall populations; (**B**) Asians; (**C**) Caucasians.](oncotarget-08-393-g004){#F4}

Sensitivity analysis {#s2_3}
--------------------

In all the included studies, nine studies were not consistent with the Hardy-Weinberg equilibrium (HWE) in controls (*P* \< 0.05) (Table [1](#T1){ref-type="table"}). Nevertheless, after conducting the sensitivity analyses, the pooled ORs were no statistically significant change when deleting any of the studies, demonstrating that our results are stable and reliable (Figure [5](#F5){ref-type="fig"}).

![Sensitivity analyses of the three microRNA polymorphisms in specific genetic models\
(**A**) rs3746444 in heterozygote genetic model; (**B**) rs11614913 in allele contrast genetic model; (**C**) rs2910164 in homozygote genetic model.](oncotarget-08-393-g005){#F5}

Heterogeneity analysis {#s2_4}
----------------------

We used Q statistic to determine the heterogeneity among studies in this meta-analysis. If significant heterogeneity existed (*P* value of *Q* test was \< 0.1), we would select random-effects model to perform related statistical analysis; if not, we would choose fixed-effects model to carry out our research.

Publication bias {#s2_5}
----------------

Begg\'s test, Egger\'s test and funnel plot were all used to assess the publication bias of the included studies. All *P* values of Begg\'s test and Egger\'s test were greater than 0.05 (*P* \> 0.05), demonstrating that there is no significant publication bias in the overall population (Table [3](#T3){ref-type="table"}). Funnel plot also proved that publication bias did not exist with no obvious asymmetry that could be observed (Figure [6](#F6){ref-type="fig"}). Hence, no publication bias was found in this meta-analysis. Egger\'s publication bias plots are shown in Figure [7](#F7){ref-type="fig"}.

![Funnel plots of the three microRNA polymorphisms in specific genetic models\
(**A**) rs3746444 in dominant genetic model; (**B**) rs11614913 in heterozygote genetic model; (**C**) rs2910164 in heterozygote genetic model.](oncotarget-08-393-g006){#F6}

![Egger\'s publication bias plots of the three microRNA polymorphisms in specific genetic models\
(**A**) rs3746444 in heterozygote genetic model; (**B**) rs11614913 in allele contrast genetic model; (**C**) rs2910164 in homozygote genetic model.](oncotarget-08-393-g007){#F7}

DISCUSSION {#s3}
==========

With the development of science and the improvement of medical technology, the diagnosis and treatment of breast cancer has made great progress in the past years. However, its pathogenesis has not been completely elucidated yet. Breast cancer is a highly heterogeneous disease. Its occurrence and development involves oncogene activation, tumor suppressor gene inactivation and many other related factors. In recent years, many microRNA polymorphisms have been identified as risk factors for breast cancer \[[@R29], [@R30]\].

Currently, three well-known SNPs in microRNA (rs3746444, rs11614913 and rs2910164) have been widely investigated and found to be associated with the risk of several types of cancer \[[@R31]--[@R33]\]. Nevertheless, the relationship between these three miRNA polymorphisms and BC risk can\'t be determined because of inconsistent results published articles reported. Consequently, in order to obtain a more precise evaluation of the relationship, we perform this meta-analysis.

The microRNA-499 rs3746444 polymorphism is located in chromosome 20q11.22, which is an A to G single-nucleotide mutation that occurs in the stem structure of miR-499 precursor \[[@R34]\]. Studies have shown that rs3746444 can regulate the expression of SOX genes \[[@R35]\]. The abnormal expression of SOX genes can activate Wnt/β-catenin signaling pathway, which is associated with breast tumorigenesis and progression, so rs3746444 may play an important role in the occurrence and development of breast cancer by altering SOX genes\' expression level. Several studies \[[@R9], [@R13], [@R15]--[@R16]\] reported that rs3746444 polymorphism had an increased association with breast cancer risk, while others \[[@R10], [@R27], [@R36]\] showed no significant association between rs3746444 and BC susceptibility. Our result indicated that SNP rs3746444 was associated with BC risk in the four genetic models except recessive genetic model. In the subgroup analysis by ethnicity, we found that rs3746444 was associated with an increased risk of BC in Asians; nevertheless, no significant association was observed in Caucasians. The result was in correspondence with that of two previously published meta-analyses \[[@R37], [@R38]\], which further demonstrates that our result is credible.

Genetic variant in miR-196a2 (rs11614913) involving a C to T nucleotide substitution can alter its expression and function, which is associated with cancer susceptibility. Studies have reported that miR-196a can repress HOX gene expression through directing its mRNA cleavage \[[@R39]\]. Recent studies have found that HOXBP is overexpressed in breast cancer and it can promote invasion and metastasis of breast cancer \[[@R40]\]. Besides, the study by Seki et al. demonstrated that HOXBP was a significant prognostic factor in BC \[[@R41]\]. However, published studies showed inconsistent results on the association between rs11614913 and BC risk. Dai et al. \[[@R16]\] reported that rs11614913 polymorphism was a protective factor of BC. On the contrary, rs1614913 was found to be associated with an increased risk of BC in other studies \[[@R9], [@R14]\]. In our study, no correlation was detected between this polymorphism and breast susceptibility in the overall populations. However, in the subgroup analysis by ethnicity, we observed that rs11614913 was associated with a decreased risk of breast cancer among Caucasians in allele contrast genetic model. Our finding was partly consistent with the results of three previously published meta-analyses: in the meta-analysis by Chen et al. \[[@R42]\], twelve studies were included and the result showed that rs11614913 was a protective factor of BC in Asians; in other two meta-analyses \[[@R27]--[@R28]\], ten studies and eight studies were included, respectively, demonstrating that the rs11614913 polymorphism could decrease the BC risk in the overall populations. Compared with them, our study included eighteen eligible studies so our result was more reliable with the larger sample size. But consider the obvious heterogeneity among the included studies, we should cautiously treat our result although sensitivity analysis demonstrated that our result was stable.

For rs2910164, we observed that there was no association between rs2910164 and breast cancer risk in the general populations. When stratified by ethnicity, similar results could be seen in both Asians and Caucasians. Nevertheless, in a previous meta-analysis by Dai et al. \[[@R28]\], the authors found that the rs2910164 polymorphism had a significant association with BC risk in Caucasians using the homozygote comparison model and the dominant model. This contradiction may be due to different sample sizes and racial groups of the two studies: compared with his study, our study includes five new case-control studies, which will expand the sample size and thus get a more precise evaluation of association between rs2910164 and BC risk.

Some limitations of this meta-analysis must be pointed out. First, several important individual information was not provided, thus we couldn\'t perform a more accurate analysis stratified by other risk factors of breast cancer such as age, gender, lifestyle and environmental factor. Meanwhile, a few studies selected specific type of breast cancer as the subjects of case group: the study by Ma et al. focused on triple negative breast cancer \[[@R21]\]; study by Catucci et al. only involved familial BC \[[@R10]\]. Second, some studies didn\'t conform to Hardy-Weinberg equilibrium (HWE) in controls, which might influence the reliability of the results. Third, the variety of genotyping methods used in the included studies might have an impact on the results of our study. Last, obvious between-study heterogeneity existed in the included studies, and its sources were not clear. Moreover, not sufficient studies also made it difficult to make a more accurate assessment of these three polymorphisms and breast cancer susceptibility.

In summary, this meta-analysis indicates that miR-499 rs3746444 is associated with an increased BC risk in Asians and in the overall populations, while miR-196a rs11614913 has a decreased association with breast cancer risk among Caucasians. Besides, miR-146a rs2910164 has no relationship with breast cancer susceptibility. More multicenter studies with larger sample sizes are needed to further confirm the possible roles of these three microRNA polymorphisms in breast cancer.

MATERIALS AND METHODS {#s4}
=====================

Literature and search strategy {#s4_1}
------------------------------

We searched PubMed, EMBASE and Web of Science databases for papers published before September 18, 2016. There were no language restrictions in our searching process. The searching strategy was as follow: (breast cancer OR breast carcinoma) AND (polymorphism OR variant OR genotype OR SNP) AND (miR-499 OR rs3746444 OR miR-196a OR rs11614913 OR miR-146a OR rs2910164). Besides, the references of the retrieved studies were also reviewed to find additional eligible publications.

Inclusion criteria {#s4_2}
------------------

All included studies must meet the following criteria: (1) evaluation of these three microRNA polymorphisms (miR-499 rs3746444, miR-196a rs11614913 and miR-146a rs2910164) and BC risk; (2) case-control studies; (3) sufficient genotyping data that could be used to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (4) all the breast cancer subjects in case groups must be pathologically confirmed. The exclusion criteria were: (1) not case-control studies; (2) case reports, editorials, comments or review articles; (3) duplicate studies; (4) no detailed genotyping data.

Data extraction {#s4_3}
---------------

Two investigators independently extracted the data from the included studies, and discrepancies were resolved through discussion with a third researcher. The following information was extracted: the first author, year of publication, country of origin, ethnicity, genotyping method, number of cases and controls, and *P* value for Hardy-Weinberg equilibrium (HWE).

Statistical analysis {#s4_4}
--------------------

The association of these three functional microRNA polymorphisms with BC susceptibility was measured by pooled odds ratios (ORs) and 95% confidence intervals (CIs) in five genetic models, including a allele contrast genetic model, a homozygote genetic model, a heterozygote genetic model, a dominant genetic model, and a recessive genetic model. Heterogeneity among studies was evaluated by *I*^2^ test and *Q* test. For *I*^2^ test, the criteria for heterogeneity were as follows: *I*^2^ \< 25%, no heterogeneity; 25%-75%, moderate heterogeneity; *I*^2^ \> 75%, high heterogeneity. If the *P value* of *Q* test was \< 0.1, the random-effects model was used; otherwise, the fixed-effects model was applied. Sensitivity analysis was performed by sequentially deleting each study at a time to assess the influence of each study on the pooled ORs. We used Begg\'s test, Egger\'s test and funnel plot to assess publication bias. *P value* for Hardy-Weinberg equilibrium (HWE) was calculated by chi-square test in the control group of each study. Subgroup analysis was performed according to ethnicity. All statistical analyses were performed using STATA version 10.0 software (StataCorp LP, College Station, TX, USA). All *P* values were two sided, and *P* \< 0.05 was considered statistically significant.
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